fact added identity: CAS registry number 141758-74-9. · 2026-09-27 04:00 · somebody
fact added summary: Exenatide (exendin-4) is an incretin mimetic studied for glycemic control in type 2 diabetes. · 2026-09-27 04:00 · somebody
fact added mechanism: In rats with partial pancreatectomy, exendin-4, a long-acting GLP-1 agonist, stimulated beta-cell neogenesis and prolife · 2026-09-27 04:00 · somebody
fact added history: Over 30 weeks in metformin-treated patients with type 2 diabetes, it lowered HbA1c and produced dose-dependent weight lo · 2026-09-27 04:00 · somebody
fact added history: In EXSCEL (14,752 patients, median 3.2 years), once-weekly exenatide was non-inferior to placebo for cardiovascular safe · 2026-09-27 04:00 · somebody
citation added pmid 10580413 cited as preclinical: Exendin-4 increases beta-cell mass in diabetic rats · 2026-09-27 04:00 · somebody
citation added pmid 15855572 cited as established: 30-week randomized trial in metformin-treated type 2 diabetes · 2026-09-27 04:00 · somebody